<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814733</url>
  </required_header>
  <id_info>
    <org_study_id>RAP-PK-18</org_study_id>
    <nct_id>NCT03814733</nct_id>
  </id_info>
  <brief_title>Assessment of Effect of Rapastinel on Driving Performance</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Double-dummy, Placebo-controlled, 5-period, Crossover Study Assessing the Effects of Rapastinel Compared to Alprazolam, Ketamine, and Placebo on Simulated Driving Performance in Normal Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naurex, Inc, an affiliate of Allergan plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naurex, Inc, an affiliate of Allergan plc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the pharmacological class of rapastinel, this study will be conducted to evaluate
      the participant's driving performance after single IV doses of rapastinel as compared with
      single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and
      placebo in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Actual">April 3, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Simulated driving performance as measured by SDLP using the CRCDS-MiniSim for rapastinel compared with placebo and positive control (alprazolam)</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>simulated driving performance as measured by SDLP using the CRCDS-MiniSim for rapastinel compared with a clinical comparator (ketamine)</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleepiness Scale (KSS)</measure>
    <time_frame>Day 1 of each intervention</time_frame>
    <description>The KSS is a participant self-reported measure of situational sleepiness and provides an assessment of alertness/sleepiness. The KSS is a 9-point categorical scale, where 1 = &quot;extremely alert&quot; and 9 = &quot;extremely sleepy-fighting sleep&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-perceived safety to drive (&quot;Right now do you feel safe to drive?)</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale to assess participant's motivation and self-appraisal of their driving performance</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CogScreen SDC Test</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of abnormal lane exceedance events</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Speed (mph)</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total collisions</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exceeded cornering speed threshold events</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Divided attention: average number of correct responses</measure>
    <time_frame>Day 1 of each intervention</time_frame>
    <description>Participants are asked to answer periodic questions during the driving simulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Divided attention: average number of errors</measure>
    <time_frame>Day 1 of each intervention</time_frame>
    <description>Participants are asked to answer periodic questions during the driving simulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Divided attention: average reaction time</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapastinel blood plasma concentration</measure>
    <time_frame>Day 1 of each intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 66 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of abnormal electrocardiograms</measure>
    <time_frame>Up to 66 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale</measure>
    <time_frame>Up to 66 days</time_frame>
    <description>The C-SSRS is a clinician-ratedinstrument that reports theseverity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (least severe) to 5 (most severe).</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Driving Performance</condition>
  <arm_group>
    <arm_group_label>Rapastinel High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapastinel Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alprazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Rapastinel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Alprazolam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Ketamine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapastinel</intervention_name>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
    <arm_group_label>Rapastinel High Dose</arm_group_label>
    <arm_group_label>Rapastinel Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
    <arm_group_label>Alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapastinel Matched Placebo</intervention_name>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
    <arm_group_label>Placebo for Rapastinel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam Matched Placebo</intervention_name>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
    <arm_group_label>Placebo for Alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Matched Placebo</intervention_name>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.</description>
    <arm_group_label>Placebo for Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Participant possesses a valid driver's license and is an active driver. Drives a
             minimum of 5,000 miles (about 8,000 km) per year for the previous 3 years.

          -  Participant has a regular sleep pattern, is not engaged in shift-work, and in general,
             has at least 7 hours of sleep each night (bedtime occurs between 21:00 and 24:00
             hours).

        Exclusion Criteria

          -  A history within 2 years of, or current intervention for, a sleeping disorder
             (including excessive snoring, obstructive sleep apnea) or a chronic painful condition
             that interferes with the participant's sleep.

          -  A history of difficulty in falling asleep or staying asleep in the previous 3 months
             that is considered clinically significant by the investigator.

          -  Participant has traveled across 1 or more time zones (transmeridian travel) in the 14
             days before study intervention or is expected to travel across 1 or more time zones
             during the study.

          -  Expected to work on a rotating shift during their participation in the study.

          -  Participant works a night shift.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheng Fang Su</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>San Clemente</city>
        <state>California</state>
        <zip>92673</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Aurora</city>
        <state>Ontario</state>
        <zip>L4G 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

